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Atherosclerotic diseases account for nearly half of all deaths and are leading causes of adult
disability. Our understanding of how atherosclerosis leads to cardiovascular disease events has
evolved: from a concept of progressive luminal narrowing, to that of sudden rupture and
thrombosis of biologically active atheroma. In concert with this conceptual shift, contemporary
imaging techniques now allow imaging of biological processes that associate with plaque
instability: active calcification and plaque inflammation. This review focuses on opportunities
provided by positron emission tomography/computed tomography, to identify these high-risk
biological features of atherosclerosis.
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MI Myocardial infarction
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PET Positron emission tomography
VCAM Vascular cell adhesion molecules
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INTRODUCTION
Despite advances in cardiovascular therapeutics,
atherosclerotic events, such as myocardial infarction
(MI) and stroke, continue to account for nearly half of
all deaths and are a leading cause of adult disability.
Decades’ worth of scientific studies refined our under-
standing of how atherosclerotic disease results in
atherothrombotic events: from a concept of progressive
luminal narrowing to that of sudden rupture and throm-
bosis of biologically active atheroma. In concert with
this conceptual shift, the approach to imaging
atherosclerotic milieu has moved beyond lumenological
imaging and now incorporates identification of high-risk
features of the arterial wall, including structural features,
along with key biological processes (such as active
calcification and plaque inflammation).1,2 This review
focuses on opportunities provided by positron emission
tomography/computed tomography (PET/CT) to char-
acterize such biological features of high-risk
atherosclerotic plaque.
ATHEROSCLEROTIC PLAQUE BIOLOGY3
Atherosclerotic plaques are biologically active tis-
sues. Oxidized low-density lipoprotein (LDL) particles
induce endothelial cells to express leukocyte adhesion
molecules (e.g., vascular cell adhesion molecules-1 or
VCAM-1, selectins). These adhesion molecules prompt
recruitment of circulating monocytes and T-lympho-
cytes that in turn release cytokines and magnify the
inflammatory cascade. Monocytes differentiate into
resident macrophages, which phagocytose oxidized
LDL and subsequently evolve into foam cells. As
inflammatory cells and lipids accumulate within the
atheroma, the plaque enlarges. Macrophages and smooth
muscle cells undergo apoptosis, and their discarded
lipids add to the evolving lipid-rich necrotic core.
Neovascularization is triggered by hypoxia and is
considered a marker of ongoing disease activity and
indicative of a high-risk plaque. These new microves-
sels, originating from the adventitial vasa vasorum, are
immature and leaky resulting in local intra-plaque
Figure 1. Molecular targets for positron emission tomography atherosclerosis imaging. During
atherosclerosis development macrophages avidly utilize glucose, and simultaneously accumulate
18F-fluorodeoxyglucose (FDG). 18F-fluorodeoxymannose also accumulates in macrophages,
entering via glucose transporters and mannose receptors. Somatostatin receptors are also expressed
on activated macrophages, and act as a target for the tracer 68 Ga-DOTATATE. Macrophages-
mediated inflammation can also be detected by novel tracers targeting translocator protein receptors
(11C-PK11195) and macrophage cell membranes (18F-FMCH). Additional positron emission
tomography tracers targeting atherosclerosis can identify microcalcification (18F-sodium fluoride),
neoangiogenesis (68 Ga-NOTA-RGD, 18F-Galacto-RGD), and cellular hypoxia (18F-FMISO).
Reprinted with permission1.
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hemorrhage. Active calcium deposition represents
another common feature of vulnerable plaque. Eventu-
ally, the production of matrix metalloproteinases by
activated leukocytes leads to enzymatic degradation of
the plaque’s fibrous cap. This disruption can prompt
plaque rupture, leading to atherothrombotic conse-
quences. Accordingly, atherosclerotic plaques provide
several attractive targets for imaging biological activity
(Figure 1).
IMAGING OF VASCULAR INFLAMMATIONWITH
(FDG-PET/CT)1,4
18F-flurodeoxyglucose (FDG) has been validated as a
tracer for imaging vascular inflammation. The radio-
labeled glucose analogue accumulates in glycolytically
active cells and is used in clinical PET imaging to identify
metabolically active tissue such as tumors and inflamma-
tory foci. Both pre-clinical and human studies show that
Figure 2. Example positron emission tomography images demonstrating high and low arterial 18F-
fluorodeoxyglucose uptake in two individuals. One individual, who experienced a subsequent CVD
event after imaging, (A and C), demonstrated high carotid FDG uptake (white arrow, A) and high
aortic FDG uptake (white arrow, C) prior to that event. In contrast, a second individual who did not
experience a subsequent, (B and D) manifested low arterial FDG uptake. Reprinted with
permission1.
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the uptake of FDG within the artery wall correlates with
macrophage accumulation in arterial plaques. Several
studies have shown that FDG-PET/CT imaging of arterial
inflammation provides potent prognostic information to
predict the risk of developing cardiovascular disease
(CVD) events. Figueroa et al. demonstrated in cancer-free
patients that aortic FDG uptake predicts incident CVD
beyond traditional risk factors and coronary calcium
scores. Furthermore, in patients with recent stroke sec-
ondary to carotid atherosclerosis, carotid inflammation
independently predicts recurrent stroke. (Figures 2, 3)
ROLE OF FDG-PET/CT IN MONITORING NOVEL
THERAPIES1
Measurement of arterial inflammation with FDG-
PET/CT has been shown to be highly reproducible. As a
result, it has been widely employed as a research tool to
assess the impact of anti-atherosclerotic interventions. A
non-randomized single center FDG-PET/CT study first
reported a reduction in arterial inflammation following
3 months of low-dose statin therapy. A subsequent
multi-center study demonstrated a graded anti-inflam-
matory action of high-dose vs low-dose atorvastatin.
These PET/CT findings are in concert with the wealth of
clinical endpoint trial data showing statins’ beneficial
impact on CVD events. Similarly thiazolidinediones
have been shown to reduce arterial inflammation in
patients with type 2 diabetes mellitus and significantly
reduce CVD events in this group.
Conversely, a cholesterol ester transfer protein
modulator (dalcetrapib), lipoprotein-associated phos-
pholipase A2 inhibitor (rilapladib), and P-38 MAP
kinase antagonists (BMS-582949 and losmapimod) each
failed to significantly reduce arterial inflammation in
PET/CT trials (with the notable exception of post hoc
exploratory endpoints). Congruently, large clinical end-
point trials have shown that compounds in the same drug
class so far also have failed to reduce CVD events.
Accordingly, FDG-PET/CT trials have the potential to
quantify therapeutic efficacy for novel drug discovery
and treatment strategies.
Figure 3. Proportion of participants who remained free from a cardiovascular event after an initial
arterial 18F-fluorodeoxyglucose positron emission tomography scan. Arterial inflammation was
determined as aortic FDG uptake corrected for background activity. Increased aortic inflammation
on the baseline scan (a value within the highest tertile) associated with a higher risk of a subsequent
cardiovascular event (median follow-up of 4.2 years). Reprinted with permission1.
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IMAGING OF VASCULAR CALCIFICATION1,2
Vascular calcification is another important feature
of atherosclerotic disease. Importantly, the associated
risk attributable to vascular calcification diverges
according to the size of the calcification. Microcalcifi-
cation (deposits of calcification smaller than 50 lm)
occurs predominantly in the fibrous cap and may
contribute to mechanical plaque destabilization while
macrocalcification may confer plaque stability1. While
macrocalcification is detectable using conventional
medical imaging, microcalcification cannot be detected
on structural imaging. New techniques are required in
order to detect and quantify the microcalcification
process non-invasively in vivo.
18F-sodium fluoride (NaF) is a PET/CT radiotracer
used in oncology to detect metastatic bone spread, where
18F-fluoride replaces the hydroxyl groups in hydroxya-
patite. Within atheroma, microcalcification is largely felt
to be an active process driven by osteoblast-like cells
derived from vascular smooth muscle, though passive
deposition of calcium phosphate deposits resulting from
phosphate release from necrotic cells may also play a
role. It is believed that NaF is incorporated into
hydroxyapatite at the sites of active microcalcification
sites in a similar manner to that seen in its oncology
applications. This process is likely accelerated by
inflammation, with plaque macrophage burden strongly
associated with osteoblastic activity in the aorta of
hyperlipidemic mice.1
Several studies have demonstrated NaF-PET/CT’s
utility to detect microcalcification. Such studies show
that NaF localizes to sites of active microcalcification
(rather than simply reflecting the burden of calcifica-
tion). Clinical studies have shown NaF uptake
(measured by tissue-to-background ratios) is higher in
symptomatic and high-risk atheroma compared to
asymptomatic atheroma in both coronary and carotid
arteries (Figure 4).
The development of techniques capable of imaging
microcalcification has the potential to improve CVD
risk, prognosis and guide the identification of new
Figure 4. Coronary artery culprit lesions manifest increased 18F-sodium fluoride. 18F-sodium
fluoride uptake was evaluated, using PET, in individuals who had a recent myocardial infarction.
Two patients, (A and C), manifested culprit lesions in the left anterior descending artery (red
arrows in A and C). 18F- sodium fluoride imaging in those same individuals (B and D) shows
intense 18F-sodium fluoride activity in the same locations. E shows group mean data, which
demonstrate elevated 18F-sodium fluoride activity in the culprit lesions compared to non-culprit
vessels in the same individuals. Reprinted with permission1.
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therapeutic strategies. Dweck et al. demonstrated that
patients with higher vascular 18NaF uptake are more
likely to have a clinical diagnosis of coronary artery
disease and higher Framingham risk scores, with a
correlation between NaF uptake and coronary artery
calcium score, leading the authors to suggest NaF uptake
could be used to refine CVD risk.
FUTURE CONSIDERATIONS1
Several newer tracers have been evaluated for
imaging high-risk biological features of atherosclero-
sis. 68Ga-DOTATATE targets the somatostatin
receptor2, which is over-expressed in activated macro-
phages and endothelial cells responsible for
inflammation and angiogenesis. This novel tracer has
advantages over FDG for imaging coronary atheroma,
since it is not taken up by myocardium. Additional
tracers that target macrophages include 11C-PK11195
(targeting TSPO receptor), and 18F-FMCH (targeting
macrophages cell membrane) have been shown in pre-
clinical studies to localize to areas of active inflam-
mation. Hypoxia within the plaque stimulates new
vessel formation, increases LDL oxidation and pro-
motes a pro-inflammatory response in macrophages.
Hypoxia can be identified using 18F-fluoromisonidazole
(18F-FMISO), a new tracer that identified cellular
hypoxia as demonstrated by increased aortic uptake
in an animal model fed an atherogenic diet. Neoangio-
genesis can also be detected, using a tracer targeting
integrin avb3expression (e.g., 68Ga-NOTA-RGD and
18F-Galacto-RGD).
As new therapies are developed (such as PCSK9
antagonists, along with other novel compounds drugs
that may have more than minimal side effects), there
will be a greater need for enhanced risk stratification.
With such theoretical expansion of treatment options,
there will be a need to better-match an individual’s
risk against the cost and side effects of the new
treatments. Additionally, imaging may be needed in
order to assess whether the dose of the new therapies
should be changed, or switched altogether, depending
on changes seen on serial imaging, much the same
way such decisions are made in oncologic diseases.
Imaging biological features of atherosclerosis may
contribute importantly to such enhanced risk
assessment.
CONCLUSION
PET/CT imaging provides outstanding opportuni-
ties to assess atherosclerotic plaque biology non-
invasively. Current use of FDG and NaF enables the
early detection of atherosclerotic plaque inflammation
and microcalcification. Such an approach enhances our
assessment of individual risk, and may help identify new
therapies. Additional studies are needed to delineate the
potential clinical role of such approaches especially as
armamentarium to treat atherosclerotic disease growth,
placing demands on better delineation of risk and a
better understanding of treatment response.
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